Adriano Lazzarin
A5021984756- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- HIV/AIDS Research and Interventions
- Hepatitis C virus research
- HIV-related health complications and treatments
- Pneumocystis jirovecii pneumonia detection and treatment
- Immune Cell Function and Interaction
- Cytomegalovirus and herpesvirus research
- Liver Disease Diagnosis and Treatment
- Hepatitis B Virus Studies
- Viral-associated cancers and disorders
- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- HIV, Drug Use, Sexual Risk
- Lymphoma Diagnosis and Treatment
- Polyomavirus and related diseases
- Blood groups and transfusion
- Tuberculosis Research and Epidemiology
- Herpesvirus Infections and Treatments
- T-cell and B-cell Immunology
- Mycobacterium research and diagnosis
- Syphilis Diagnosis and Treatment
- Immunotherapy and Immune Responses
- T-cell and Retrovirus Studies
- Pharmacological Effects and Toxicity Studies
Italian Oncology Group of Clinical Research
2024
University of Parma
1990-2024
Vita-Salute San Raffaele University
2014-2023
San Raffaele University of Rome
2012-2023
Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele
2014-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2014-2023
Triple O Medical Services
2023
University College Dublin
2023
Office of Infectious Diseases
1987-2021
Italian Medicines Agency
2018
Hepatitis C virus (HCV) infection is highly prevalent and associated with substantial morbidity mortality among persons infected the human immunodeficiency (HIV). We compared efficacy safety of pegylated interferon alfa-2a (peginterferon alfa-2a) plus either ribavirin or placebo those for treatment chronic HCV in patients who were also HIV.A total 868 both HIV had not previously been treated randomly assigned to receive one three regimens: peginterferon (180 microg per week) (800 mg day),...
Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs.We conducted two identical trials in different geographic regions evaluate the safety and efficacy raltegravir, as compared with placebo, combination optimized background therapy, patients infected that has triple-class drug resistance whom therapy had failed. Patients were randomly assigned raltegravir placebo a 2:1...
The T-20 vs. Optimized Regimen Only Study 2 (TORO 2) compared the efficacy and safety of 24 weeks treatment with fusion inhibitor enfuvirtide in combination an optimized background antiretroviral regimen alone.
We evaluated the efficacy of raltegravir and development viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1 (HIV-1) triple-class drug whom antiretroviral therapy had failed.
Background. Abacavir-lamivudine and tenofovir DF-emtricitabine fixed-dose combinations are commonly used as first-line antiretroviral therapies. However, few studies have comprehensively compared their relative safety profiles.
We conducted subanalyses of the combined results Maraviroc versus Optimized Therapy in Viremic Antiretroviral Treatment-Experienced Patients (MOTIVATE) 1 and MOTIVATE 2 studies to better characterize efficacy safety maraviroc key subgroups patients.We analyzed pooled data from week 48 two according sex, race or ethnic group, clade, CC chemokine receptor 5 (CCR5) delta32 genotype, viral load at time screening, use nonuse enfuvirtide optimized background therapy (OBT), baseline CD4 cell count,...
Objective: To characterize the safety profile of tenofovir disoproxil fumarate (DF) for treatment HIV infection in adults over first 4 years use. Methods: A DF expanded access program (EAP) was initiated 2001; data were examined from this and manufacturer's database, which contained reports all postmarketing adverse drug reactions received up to 30 April 2005. Specific analyses performed renal DF. Results: The EAP enrolled 10 343 patients; serious events (SAEs) reported 631 (6%). SAE any...
Background. The pilot phase IIb VIKING study suggested that dolutegravir (DTG), a human immunodeficiency virus (HIV) integrase inhibitor (INI), would be efficacious in INI-resistant patients at the 50 mg twice daily (BID) dose. Methods. VIKING-3 is single-arm, open-label III which therapy-experienced adults with received DTG BID while continuing their failing regimen (without raltegravir or elvitegravir) through day 7, after was optimized ≥1 fully active drug and continued. primary efficacy...
Background. Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG HIV-1–infected subjects with genotypic evidence RAL resistance. Methods. Subjects received 50 mg once daily (cohort I) or twice II) while continuing failing regimen (without RAL) through day 10, after which background was optimized, when feasible, for...
BackgroundBictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is a single-tablet regimen recommended for HIV-1 treatment. The safety and efficacy of B/F/TAF as initial therapy was established in two Phase 3 studies: 1489 (vs dolutegravir [DTG]/abacavir/lamivudine) 1490 DTG + F/TAF). After 144 weeks randomized follow-up, an open-label extension evaluated to 240 weeks.MethodsOf 634 participants B/F/TAF, 519 completed the double-blinded treatment, 506/634 (80%) chose 96-week extension,...
It is possible that antiretroviral treatment given early during primary infection with the human immunodeficiency virus (HIV) may reduce acute symptoms, help preserve immune function, and improve long-term prognosis.
Background: Atazanavir, an azapeptide protease inhibitor (PI), has pharmacokinetics that allow once-daily dosing, and it is not associated with significant PI-associated dyslipidemia. Methods: A randomized, double-blind, double-dummy, active-controlled, 2-arm study comparing the antiviral efficacy safety of atazanavir 400 mg administered once daily efavirenz 600 in combination open-label fixed-dose zidovudine plus lamivudine twice daily. The 810 treatment-naive patients were stratified by...
Following infection of the host with a virus, delicate balance between virus replication/spread and immune response to determines outcome infection, i.e., persistence versus elimination virus. It is unclear, however, what relative roles immunologic virologic factors play during primary viral in determining subsequent clinical outcome. By studying cohort subjects HIV it has been demonstrated that qualitative differences HIV, but not quantitative initial levels viremia are associated different...